Wang, X., Bai, Z., Deng, W., & Wang, X. (2025). Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy. Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, 43(2), 214-222. https://doi.org/10.1007/s10637-025-01510-1
Chicago-referens (17:e uppl.)Wang, Xin, Zhigang Bai, Wei Deng, och Xinfeng Wang. "Efficacy and Safety of Fruquintinib Plus Capecitabine as First-line Treatment in Patients with Metastatic Colorectal Cancer Ineligible for Intravenous Chemotherapy." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies 43, no. 2 (2025): 214-222. https://doi.org/10.1007/s10637-025-01510-1.
MLA-referens (9:e uppl.)Wang, Xin, et al. "Efficacy and Safety of Fruquintinib Plus Capecitabine as First-line Treatment in Patients with Metastatic Colorectal Cancer Ineligible for Intravenous Chemotherapy." Investigational New Drugs: Novel Anti-Cancer Therapeutics and Therapies, vol. 43, no. 2, 2025, pp. 214-222, https://doi.org/10.1007/s10637-025-01510-1.
